Patents by Inventor Alan P. Carpenter, Jr.
Alan P. Carpenter, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8557222Abstract: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.Type: GrantFiled: April 3, 2009Date of Patent: October 15, 2013Assignee: Avid Radiopharmaceuticals, Inc.Inventors: Franz F. Hefti, Daniel M. Skovronsky, Alan P. Carpenter, Jr.
-
Publication number: 20090257949Abstract: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.Type: ApplicationFiled: April 3, 2009Publication date: October 15, 2009Applicant: AVID RADIOPHARMACEUTICALS, INC.Inventors: Franz F. Hefti, Daniel M. Skovronsky, Alan P. Carpenter, JR.
-
Patent number: 7412279Abstract: This invention relates to MRI-based methods and systems useful for diagnosing and clinically assessing the presence, location, and size of cardiovascular disease-associated stationary targets, e.g., thrombi and atherosclerotic lesions, within the vascular system. Methods and systems of the invention allow for improved anatomical information to be obtained from MRI images and allow the clinician to develop more effective treatment plans. In one aspect, the invention provides a method of determining the presence or absence of a stationary target within the vascular system of a mammal wherein two MRI data sets representing images of the vascular system and the stationary target are acquired after administration of a targeted MRI contrast agent. In another embodiment, both a targeted MRI contrast agent and a vascular MRI contrast agent are administered to a mammal, and both a vascular MRI and a targeted MRI data set are acquired.Type: GrantFiled: July 30, 2002Date of Patent: August 12, 2008Assignee: Epix Pharmaceuticals, Inc.Inventors: Robert M. Weisskoff, Peter D. Caravan, Sonia Witte, Randall B. Lauffer, Alan P. Carpenter, Jr.
-
Patent number: 7332149Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: June 21, 2000Date of Patent: February 19, 2008Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Milind Rajopadhye, John A. Barrett, Alan P. Carpenter, Jr., Edward H. Cheesman, Thomas D. Harris
-
Patent number: 7179446Abstract: The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin target imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin receptor targeted imaging agent and said perfusion imaging agent.Type: GrantFiled: November 27, 2001Date of Patent: February 20, 2007Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Alan P. Carpenter, Jr.
-
Patent number: 7138104Abstract: The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.Type: GrantFiled: August 7, 2002Date of Patent: November 21, 2006Assignee: Bristol-Myers Squibb CompanyInventor: Alan P. Carpenter, Jr.
-
Patent number: 7090828Abstract: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: January 21, 2003Date of Patent: August 15, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Edward H. Cheesman, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye, Michael Sworin
-
Patent number: 7060248Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties; a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.Type: GrantFiled: August 21, 2003Date of Patent: June 13, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Alan P. Carpenter, Jr., Milind Rajopadhye
-
Patent number: 7052673Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.Type: GrantFiled: July 18, 2003Date of Patent: May 30, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D Harris, Stuart D Heminway, Shuang Liu, Singh R Prahlad
-
Patent number: 7018611Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: October 26, 2002Date of Patent: March 28, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye
-
Patent number: 6989139Abstract: Thus the present invention describes novel compounds comprising 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits and their uses in treatment of diseases associated with MMPs.Type: GrantFiled: February 14, 2001Date of Patent: January 24, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Carl P. Decicco, David J. Nelson, John A. Barrett, Alan P. Carpenter Jr., Jingwu Duan, Milind Rajopadhye
-
Patent number: 6838074Abstract: The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.Type: GrantFiled: August 7, 2002Date of Patent: January 4, 2005Assignee: Bristol-Myers Squibb CompanyInventor: Alan P. Carpenter, Jr.
-
Patent number: 6800273Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.Type: GrantFiled: January 14, 2003Date of Patent: October 5, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
-
Patent number: 6770259Abstract: The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.Type: GrantFiled: November 2, 2001Date of Patent: August 3, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Alan P. Carpenter, Jr.
-
Patent number: 6656448Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties;a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.Type: GrantFiled: February 14, 2001Date of Patent: December 2, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Alan P. Carpenter, Jr., Milind Rajopadhye
-
Patent number: 6569402Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: June 21, 2000Date of Patent: May 27, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Edward H. Cheesman, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye, Michael Sworin
-
Patent number: 6537520Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.Type: GrantFiled: June 21, 2000Date of Patent: March 25, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
-
Patent number: 6511649Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: June 21, 2000Date of Patent: January 28, 2003Inventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye
-
Patent number: 6254852Abstract: Targeted ultrasound contrast agents are described. The contrast agents are porous particles of an inorganic material containing an entrapped gas or liquid and having an average particle diameter of about 0.05 to 500 microns. The outer surfaces of the particles incorporate a targeting ligand to target delivery of the contrast agent.Type: GrantFiled: July 16, 1999Date of Patent: July 3, 2001Assignee: Dupont Pharmaceuticals CompanyInventors: Joseph L Glajch, Alan P. Carpenter, Jr., Edward H. Cheesman
-
Patent number: 4894445Abstract: A method for preparing a coordination complex of an isonitrile ligand and a radioisotope of Tc, Ru, Co, Pt, Re, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Nb and Ta from a non-radioactive metal adduct of the isonitrile.Type: GrantFiled: June 25, 1986Date of Patent: January 16, 1990Assignee: E. I. Du Pont De Nemours and CompanyInventors: Alan P. Carpenter, Jr., Leo J. Maheu, Michael A. Patz, Thomas H. Tulip, Karen E. Linder, Vinayakam Subramanyam, Jeffery S. Thompson